In the closing days of September, a European regulatory body moved to widen the circle of care for millions living with chronic inflammatory disease — recommending approval of Gobivaz, a biosimilar to the biologic golimumab, developed by Iceland's Alvotech and set to be commercialized across Europe by Advanz Pharma. The decision, still awaiting formal confirmation from the European Commission, reflects a quiet but consequential shift in modern medicine: as patents on complex biologic therapies expire, their more affordable counterparts are becoming instruments of both economic relief and expan
The Manila Times
· Sep 22, 2025
· health
· 9 min de leitura
High
Apuração: Verificado
EMA Recommends Approval of Gobivaz, Alvotech's Golimumab Biosimilar
Potential positive impact: biosimilar approval could improve patient access to affordable treatment for chronic inflammatory diseases affecting millions in Europe.
◉
Health & Medicine
8412 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Viés e Enquadramento
⚖
Press release presents EMA approval recommendation for biosimilar with minimal critical analysis, using corporate language and positive framing without addressing cost, efficacy comparisons, or market implications.
Bias Direction
center-right
Confidence
HIGH
Corporate announcement framing presented as news; uses optimistic language around 'access' and 'milestones' without independent verification or critical context; structured to amplify company messaging.
increase access for patients
important milestone
significant step forward
leading biosimilars presence
positive opinion
important treatment option
Independent medical/scientific analysis of biosimilar efficacy vs. reference drug
Patient advocacy group perspectives on pricing and actual accessibility
Competitive landscape and market impact on existing treatments
Potential concerns or limitations from regulatory bodies
Healthcare cost implications for EU systems
Timeline and likelihood of final European Commission approval
Comparison to other golimumab biosimilars in development
Impacto Geopolítico
🌎
EMA approval of Icelandic biosimilar expands European pharmaceutical competition, reducing drug costs but shifting market dynamics away from US-based innovators in inflammatory disease treatment.
Escalation Risk
low
Confidence
HIGH
European Union
Iceland
Norway
Liechtenstein
United Kingdom
United States
Biosimilar approval strengthens European pharmaceutical sovereignty and reduces dependence on US biologics pricing. Alvotech (Iceland) and Advanz Pharma (UK) gain market share from Johnson & Johnson's Simponi®, reflecting broader shift toward cost-containment in EU healthcare systems and emerging biotech competition from non-traditional pharma hubs.
Similar to generic drug revolutions in the 1980s-90s, biosimilar approvals represent democratization of expensive biologics, reducing US pharma monopolies and enabling emerging biotech nations to compete globally.
Lente Econômica
📈
EMA recommends approval of Gobivaz, a golimumab biosimilar, expanding affordable treatment options for chronic inflammatory diseases across EU/EEA, potentially reducing healthcare costs and increasing market competition.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical Manufacturing
Biotechnology
Healthcare Services
Medical Devices
Healthcare Insurance
Patients gain access to more affordable biosimilar alternatives for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis, potentially reducing out-of-pocket costs and improving treatment accessibility across EU/EEA nations.
Regulatory approval strengthens EU biosimilar market competition, supporting healthcare cost containment policies. May encourage similar approvals for other biosimilars, incentivizing generic/biosimilar development and potentially prompting reference biologic manufacturers to adjust pricing strategies.